These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

275 related items for PubMed ID: 31475468

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. TGF-β-induced stromal CYR61 promotes resistance to gemcitabine in pancreatic ductal adenocarcinoma through downregulation of the nucleoside transporters hENT1 and hCNT3.
    Hesler RA, Huang JJ, Starr MD, Treboschi VM, Bernanke AG, Nixon AB, McCall SJ, White RR, Blobe GC.
    Carcinogenesis; 2016 Nov 01; 37(11):1041-1051. PubMed ID: 27604902
    [Abstract] [Full Text] [Related]

  • 4. Gemcitabine resistance in pancreatic ductal adenocarcinoma.
    Binenbaum Y, Na'ara S, Gil Z.
    Drug Resist Updat; 2015 Nov 01; 23():55-68. PubMed ID: 26690340
    [Abstract] [Full Text] [Related]

  • 5. Signal Transducer and Activator of Transcription 3, Mediated Remodeling of the Tumor Microenvironment Results in Enhanced Tumor Drug Delivery in a Mouse Model of Pancreatic Cancer.
    Nagathihalli NS, Castellanos JA, Shi C, Beesetty Y, Reyzer ML, Caprioli R, Chen X, Walsh AJ, Skala MC, Moses HL, Merchant NB.
    Gastroenterology; 2015 Dec 01; 149(7):1932-1943.e9. PubMed ID: 26255562
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Cyclopamine reverts acquired chemoresistance and down-regulates cancer stem cell markers in pancreatic cancer cell lines.
    Yao J, An Y, Wie JS, Ji ZL, Lu ZP, Wu JL, Jiang KR, Chen P, Xu ZK, Miao Y.
    Swiss Med Wkly; 2011 Dec 01; 141():w13208. PubMed ID: 21630164
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Impact of CD36 on Chemoresistance in Pancreatic Ductal Adenocarcinoma.
    Kubo M, Gotoh K, Eguchi H, Kobayashi S, Iwagami Y, Tomimaru Y, Akita H, Asaoka T, Noda T, Takeda Y, Tanemura M, Mori M, Doki Y.
    Ann Surg Oncol; 2020 Feb 01; 27(2):610-619. PubMed ID: 31605325
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Gemcitabine: A Review of Chemoresistance in Pancreatic Cancer.
    Sarvepalli D, Rashid MU, Rahman AU, Ullah W, Hussain I, Hasan B, Jehanzeb S, Khan AK, Jain AG, Khetpal N, Ahmad S.
    Crit Rev Oncog; 2019 Feb 01; 24(2):199-212. PubMed ID: 31679214
    [Abstract] [Full Text] [Related]

  • 14. Notch signaling pathway targeted therapy suppresses tumor progression and metastatic spread in pancreatic cancer.
    Yabuuchi S, Pai SG, Campbell NR, de Wilde RF, De Oliveira E, Korangath P, Streppel MM, Rasheed ZA, Hidalgo M, Maitra A, Rajeshkumar NV.
    Cancer Lett; 2013 Jul 10; 335(1):41-51. PubMed ID: 23402814
    [Abstract] [Full Text] [Related]

  • 15. Curcumin sensitizes pancreatic cancer cells to gemcitabine by attenuating PRC2 subunit EZH2, and the lncRNA PVT1 expression.
    Yoshida K, Toden S, Ravindranathan P, Han H, Goel A.
    Carcinogenesis; 2017 Oct 01; 38(10):1036-1046. PubMed ID: 29048549
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Erlotinib prolongs survival in pancreatic cancer by blocking gemcitabine-induced MAPK signals.
    Miyabayashi K, Ijichi H, Mohri D, Tada M, Yamamoto K, Asaoka Y, Ikenoue T, Tateishi K, Nakai Y, Isayama H, Morishita Y, Omata M, Moses HL, Koike K.
    Cancer Res; 2013 Apr 01; 73(7):2221-34. PubMed ID: 23378339
    [Abstract] [Full Text] [Related]

  • 18. Melittin inhibits tumor growth and decreases resistance to gemcitabine by downregulating cholesterol pathway gene CLU in pancreatic ductal adenocarcinoma.
    Wang X, Xie J, Lu X, Li H, Wen C, Huo Z, Xie J, Shi M, Tang X, Chen H, Peng C, Fang Y, Deng X, Shen B.
    Cancer Lett; 2017 Jul 28; 399():1-9. PubMed ID: 28428074
    [Abstract] [Full Text] [Related]

  • 19. Multifunctionalized iron oxide nanoparticles for selective targeting of pancreatic cancer cells.
    Trabulo S, Aires A, Aicher A, Heeschen C, Cortajarena AL.
    Biochim Biophys Acta Gen Subj; 2017 Jun 28; 1861(6):1597-1605. PubMed ID: 28161480
    [Abstract] [Full Text] [Related]

  • 20. MutY-Homolog (MYH) inhibition reduces pancreatic cancer cell growth and increases chemosensitivity.
    Sharbeen G, Youkhana J, Mawson A, McCarroll J, Nunez A, Biankin A, Johns A, Goldstein D, Phillips P.
    Oncotarget; 2017 Feb 07; 8(6):9216-9229. PubMed ID: 27999205
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.